Clinical Report: Solving the Problem of Insolubility: Part I

Overview

The increasing complexity of drug molecules has led to a rise in poorly soluble drugs, necessitating advancements in drug delivery technologies. Innovations like KinetiSol aim to address the challenges posed by these complex compounds, which often violate Lipinski’s rule of five.

Background

As drug discovery evolves, the emergence of complex molecules has made absorption more challenging. The rise of structure-based drug design and AI has opened up previously unreachable targets, resulting in a higher prevalence of poorly soluble drugs. Understanding and improving drug solubility is crucial for effective therapeutic outcomes.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• The percentage of poorly soluble drugs in pipelines is increasing due to advancements in drug discovery technologies.
• New drug molecules often break Lipinski’s rule of five, complicating their development.
• Traditional drug delivery methods are becoming inadequate for modern, complex compounds.
• KinetiSol technology offers a novel approach to overcoming solubility challenges.
• Factors affecting solubility include molecular structure, lipophilicity, and crystal habit.

Clinical Implications

Healthcare professionals should be aware of the increasing prevalence of poorly soluble drugs and the need for innovative delivery systems. Understanding the limitations of traditional methods can guide the selection of appropriate formulations for effective treatment.

Conclusion

The evolution of drug delivery technologies is essential to address the challenges posed by poorly soluble drugs. Continued innovation in this field will be critical for the successful development of new therapeutic agents.

References

1. Springer, 2022 -- Impact of Theobromine on the Dissolution of Uric Acid Kidney Stones
2. Springer, 2024 -- The Importance of Ionic Composition in Selecting Resuscitation Fluids
3. Springer, 2023 -- Response: Are Soluble Oligomers or Insoluble Fibrils the Key Players?
4. Springer, 2021 -- Influence of Co-Formulants on the In Vitro Absorption and Secretion of Active Ingredients in Plant Protection Products
5. USP -- Disintegration
6. IDSA, 2025 -- IDSA 2025 Guideline Update on the Treatment of Asymptomatic Histoplasma Pulmonary Nodules
7. Disintegration | USP
8. IDSA 2025 Guideline Update on the Treatment of Asymptomatic Histoplasma Pulmonary Nodules (Histoplasmomas) and Mild or Moderate Acute Pulmonary Histoplasmosis in Adults, Children, and Pregnant People
9. ASCO GU 2025: Real-World Comparison of Cost and Adherence Between Patients Receiving Low-Dose Versus Standard-Dose Abiraterone Acetate in a Safety-Net Hospital